Capivasertib
- Generic Name
- Capivasertib
- Brand Names
- Truqap
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN6O2
- CAS Number
- 1143532-39-1
- Unique Ingredient Identifier
- WFR23M21IE
- Background
Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Phase 2
Active, not recruiting
- Conditions
- Endometrioid AdenocarcinomaStage IV Uterine Corpus Cancer AJCC v8Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyDrug: CediranibDrug: CapivasertibDrug: Cediranib MaleateBiological: DurvalumabProcedure: Computed TomographyProcedure: EchocardiographyDrug: OlaparibProcedure: Multigated Acquisition Scan
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 288
- Registration Number
- NCT03660826
- Locations
- 🇺🇸
Jupiter Medical Center, Jupiter, Florida, United States
🇺🇸Sacred Heart Hospital, Pensacola, Florida, United States
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath